Esmeron and Clinical Experience

Rocuronium Bromide
Esmeron ®
Clinical experiences
Esmeron®
Clinical Experiences
• Chemistry & pharmacology
• Pharmacokinetics
• Pharmacodynamics
• Special patient groups
• Special procedures
• Safety profile
• Summary
Esmeron®
• Safety profile
• Summary
Esmeron®
Chemistry & pharmacology
OAc
+
O N
C D
N CH2
a B
CH
HO H -
Br CH2
Affinity for receptor in the NMJ
ACh-like fragment
on the D-ring OAc
+
O N
C D
N CH2
a B
CH
HO H -
Br CH2
Rocuronium
Low potency
Absence ACh-like fragment on A-ring
Replacement methyl
OAc
by allyl group
O N+
C D
N CH2
a B
CH
HO H -
Br CH2
Rocuronium
Stable solution
Replacement acetate
by hydroxy group OAc
O N+
C D
N CH2
a B
CH
HO H -
Br CH2
Rocuronium
Esmeron®
• Safety profile
• Summary
Esmeron®
Pharmacokinetics (1)
• Highly ionized, low lipid solubility
• Small central volume of distribution (VDc)  high
initial blood concentration
• Creates gradient between blood & tissues  fast
onset
• Volume of distribution at steady state (VDss)= ~
200mg/kg
• Plasma clearance (Clp) = 3.7 mg/kg/min
Esmeron®
Pharmacokinetics (2)
• Elimination
– hepatobiliary 50%
– renally 50%
• No accumulation during maintenance
infusions lasting up to 140 hours
Esmeron®
• Safety profile
• Summary
Esmeron®
Pharmacodynamics
• Rapid onset of action
• Intermediate duration of action
• Dose-response relationship
• Rapid recovery
(in 14 min from T1 25% to T1 75%)
• Reversal
(on T1 25% in 5 min from T1 25% to T1 75%)
Pharmacodynamics
Routine intubating dose
• Esmeron 0.6 mg/kg ( 2x ED 95 )
gives good to clinically acceptable
intubating conditions within 60 sec
• Mean onset time ( until maximum block)
60 - 120 sec
• Clinical duration 30 - 40 min
Pharmacodynamics
Routine infusion dose
Mean infusion rate for maintenance of

approximately 90%:
• 0.5 - 0.6 mg/kg/h in IV anesthesia
• 0.3 mg/kg/h in inhalational anesthesia
From: Shanks et al Anesthesiol 1993;78:649-51; Olkkola et al. Anesth Analg 1994;78:691-

6.
Pharmacodynamics
Rapid onset of action (1)
Low potency of rocuronium
= rapid onset of action
• A lower potency drug requires a higher bolus dose for
same effect
• Higher dose leads to higher plasma concentration
• Higher concentration of relaxant
= higher plasma to tissue gradient
= faster receptor blockade
Pharmacodynamics
9
8
Onset time (mins)
7
6
5
4
3
2
1
0
0 50 100 200 300 400 500 600 700 800
Effective dose for 90% block (mcg/kg)
Relationship between potency (mg/kg) and onset time

Pharmacodynamics
• Variation in onset/duration of block in

different muscle groups
• Onset at vocal cord adductor muscles faster
than at adductor pollicis but less intense
From: Wright et al. Anaesthesiology 1994;81;1110-5; Meistelman et al. Can. J.Anesth 1992;39;665-9
Pharmacodynamics
Onset of
neuromuscular block
at the larynx and
adductor pollicis
muscles after 0.5
mg/kg rocuronium
bromide
Pharmacodynamics
Dose-response relationship
Esmeron onset duration
(mg/kg) (min) (min)
0.3 2 15
0.45 1.5 25
0.6 1 30-40
0.9 0.75 50-55
Esmeron®
• Safety profile
• Summary
Special patients groups
Elderly
 total body water
 higher peak plasma concentration
lower drug clearance due to:
 liver blood flow, volume and metabolic capacity
 renal blood flow/ clearance and  creatinine
 prolonged recovery from NM block

From: Matteo et al. Anesth Analg 1993;77:1193-7
Pediatrics
Neonates/infants:
• less Ach stores   sensitivity to NMBA
 Vdss  lower peak drug levels  resistance to NMBA
• reduced capacity to clear drugs
Children:
• higher plasma clearance
 shorter duration of block
Special patient groups
Influence of age - overview
Varialbe Units Infnts Children Normal Elderly
Adults
Onset Sec 50 - 60 50 - 60 60 - 120 60 -120
Time
Clinical min 42 21- 29 30 - 40 42
Duration
Revover min 27 9 - 13 14 22
y Rate
Following a standard intubating dose of 0.6 mg/kg Esmeron, good to

excellent intubation conditions develop within 60 seconds
Liver disease (1)
Units Liver Normal
disease adults
N 17 21
T½-beta min 143 92
Vdss L/kg 0.25 0.21
Cl Ml/kg/min 2.7 3.7
Vdss: apparent volume of distribution at steady state; Cl: plasma clearance; T½-
beta: terminal elimination half-life; MRT: mean residence time
Adapted from: van Miert et al. Br J Clin Pharmacology 1997;44:139-44

Pharmacokinetics
Liver disease (2)
Clearance in cirrhotic patients compared to healthy adults
Plasma rocuronium (ng/ml)
10000
healthy cirrhotic
10
0 60 120 180 240 300 360 420 480
Time (min)
Adapted from Van Miert et al. Br J Clin Pharm 1997;44:139-44
Liver disease (3)
• Hepatic failure: reduced clearance
• Cirrhosis: recovery time from NM block
T1 25% 54 min (cirrh.) vs 42 min (control)
TOF 70% 115 (cirrh.) vs 76 min (control)
• Significantly reduced plasma clearance and

prolonged t ½ elim.
From: Van Miert et al. Br J Clin Pharm 1997;44:139

Renal disease (1)
Units Renal Normal Renal Normal
Failure Adults Failure Adults
N 10 10 9 9
T½-beta Min 97 71 104 97
Vdss L/kg 0.26 0.21 0.21 0.21
Cl Ml/kg/min 2.9 2.9 2.5 3.7
MRT Min NR NR 97 58
Vdss: apparent volume of distribution at steady state; Cl: plasma clearance; t½-
beta: terminal elimination half-life; MRT: mean residence time
Adapted from Szenohradszky J et al. Anesthesiol 1992;77:899-904; Cooper et al. Br J Anaesth

1993;71:222-6;
Renal disease (2)
• Only one study found a significant
longer clinical duration with Esmeron in
patients with renal failure
• It is recommended to closely monitor
the neuromuscular block in patients
with renal dysfunction
From: Robertson et al. Anesthesiol 1998;89:A987
ICU patients (1)
Issues in ICU patients:
• Slower recovery from block due to
longer drug half life
• Many patients have single/multi-organ
failure
• Co-existing medications
ICU patients (2)
Use of Esmeron in critically ill patients:
• No significant cardiovascular effects:
slightly increase in HR
• Fast onset
• Intermediate duration
• No active metabolites
ICU patients (3)
Esmeron infusions in critically ill patients:
• After prolonged administration spontaneous
recovery delayed in multi-organ failure patients
• Recovery times and clearance different from
short term infusions in surgical patients
• It is important to objectively monitor the degree
of neuromuscular block
From: Reeves et al.1999 Crit.Care Med 27suppl, Circeo et al. South Med.J 2001;94:36,
Sparr et al. Br.J.Anaesth 1997;78:267
Esmeron®
• Safety profile
• Summary
Clinical experiences
Special procedures
• Rapid Sequence Induction (RSI)
• Day care
• Neurosurgery
• Ocular surgery
• Cardiac surgery
• Cesarean section
• Surgery under hypothermic conditions
Special procedures
RSI (1)
100%
Comparison of 90%
80%
intubating
70%
conditions with
60% Fair
suxamethonium 50% Good
1.0 mg/kg and 40% Excellent
rocuronium 30%
0.6mg/kg and 20%
1.0mg/kg 10%
0%
Sux Roc Roc
1mg/kg 1.0mg/kg
0.6mg/kg
Adapted from: McCourt et al 1998Anaesthesia 53:867-87)
Special procedures
RSI (2)
Esmeron in doses of 0.9-1.2mg/kg provides

equally acceptable onset times and
intubating conditions to suxamethonium
1mg/kg in both adults and children
From: Mazurek etal. Anesth Analg 1998;87:1259-62; Laurin et al. Acad EMerg MEd 2000;7:1362-
9
Special procedures
Day case anesthesia
• Short clinical duration and rapid recovery
are important
• 0.3 - 0.45 mg/kg Esmeron:
– Intubation within 90 seconds
– Duration of action = 14 - 22 min.
From: Chetty et al. Anaesth Intensive Care 1996;24:37-41; Pollard et al. Eur J Anaesth
1995;12:81-3; Prien et al. Eur J Anaesth 1995;12:85-90
Special procedures
Ocular and neurosurgery
Ocular surgery
• Esmeron has no effect on Intra-Ocular
Pressure (IOP)
Neurosurgery
• Esmeron has no effect on Intra-Cranial
Pressure (ICP)
From: Robertson et al. Eur J Anaesth 1994;11:116-21; Schramm et al. Br J Anaesth
1996;76:607-11
Special procedures
Cardiac surgery
• Esmeron has no cardiovascular effects

• Esmeron is rapidly and consistently
reversable, therefore it is suitable for
fast track anesthesia
Special procedures
Cesarean Section
• Similar pharmacokinetics to other adults
• Clearance unaltered
• Minimal transplacental transfer :
UV/ MV concentration ratio rocuronium
= 0.18 (vecuronium = 0.11)
Special procedures
Hypothermic conditions
Plasma clearance significantly reduced:
2.2 ml/min/kg in hypothermia
vs. 4.3 ml/kg/min in normothermia
Note: all NMBAs show prolonged duration

under hypothermic conditions.
Esmeron®
• Safety profile
• Summary
Safety profile
Hemodynamics
• Minimal cardiovascular side effects

even at high doses
• Slightly vagolytic
i.e. small increase in heart rate
From: McCoy et al. Can J Anaesth 1993;40:703-8 and Levy et al. Anesth Analg 1994;78:318-
21
Safety profile
Histamine release
30 0.6 mg/kg
0.9 mg/kg
2.5
Plasma Histamine (ng/ml)
1.2 mg/kg
2.0
1.5
Minimal histamine release
even at higher doses
1.0
0.5
0
0 1.0 2.0 3.0 4.0 5.0
Time (min)
Adapted from: Levy et al. Anesth Analg 1994;78:318-21

Esmeron®
• Safety profile
• Summary
Esmeron®
Summary
• Rapid onset
• Intermediate duration of action
• Effective & consistently good intubation
conditions
• Safe
• Flexible - all procedures
• Titratable dosage - varying duration of action

Esmeron and Clinical Experience

Hochgeladen von

Dokumentinformationen

Originalbeschreibung:

Copyright

Verfügbare Formate

Dieses Dokument teilen

Dokument teilen oder einbetten

Freigabeoptionen

Stufen Sie dieses Dokument als nützlich ein?

Sind diese Inhalte unangemessen?

Copyright:

Verfügbare Formate

Esmeron and Clinical Experience

Hochgeladen von

Copyright:

Verfügbare Formate

Rocuronium Bromide

Mean infusion rate for maintenance of

From: Shanks et al Anesthesiol 1993;78:649-51; Olkkola et al. Anesth Analg 1994;78:691-

Relationship between potency (mg/kg) and onset time

• Variation in onset/duration of block in

 prolonged recovery from NM block

Following a standard intubating dose of 0.6 mg/kg Esmeron, good to

Adapted from: van Miert et al. Br J Clin Pharmacology 1997;44:139-44

• Significantly reduced plasma clearance and

From: Van Miert et al. Br J Clin Pharm 1997;44:139

Cl Ml/kg/min 2.9 2.9 2.5 3.7

Adapted from Szenohradszky J et al. Anesthesiol 1992;77:899-904; Cooper et al. Br J Anaesth

Esmeron in doses of 0.9-1.2mg/kg provides

• Esmeron has no cardiovascular effects

Note: all NMBAs show prolonged duration

• Minimal cardiovascular side effects

Adapted from: Levy et al. Anesth Analg 1994;78:318-21

Das könnte Ihnen auch gefallen